Previous close | 12.08 |
Open | 11.94 |
Bid | 11.17 x 900 |
Ask | 12.25 x 1200 |
Day's range | 11.19 - 12.01 |
52-week range | 8.02 - 18.68 |
Volume | |
Avg. volume | 103,022 |
Market cap | 496.293M |
Beta (5Y monthly) | 0.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.06 |
Earnings date | 07 Nov 2023 - 13 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 27.25 |
Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CAMBRIDGE, Mass. & MONTREAL, September 19, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will present initial data from Module 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial in a plenary session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston, MA. In addition to this presentation, the Company will
CAMBRIDGE, Mass. & MONTREAL, September 06, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023, at 11:30 a.m. Eastern Time in New York, NY.